Literature DB >> 10682228

Diurnal motor variations to repeated doses of levodopa in Parkinson's disease.

U Bonuccelli1, P Del Dotto, C Lucetti, L Petrozzi, S Bernardini, G Gambaccini, G Rossi, P Piccini.   

Abstract

Patients with Parkinson's disease (PD) in long-term levodopa therapy often complain of worsening of motor symptoms in the afternoon and evening. The pathophysiology of this phenomenon is not known. We evaluated the motor response to repeated doses of levodopa during a 12-hour period in 52 parkinsonian patients (19 de novo, 20 stable, and 13 wearing-off). On the day of the study, all patients received standard doses of levodopa/carbidopa at 8:00 a.m., 12:00 noon, and 4:00 p.m. Motor measurements such as tapping test, walking time, and tremor score, and blood samples for levodopa and 3-O-methyldopa (3OMD) plasma analysis, were performed hourly. Mean motor scores and pharmacokinetic data, evaluated for a period of 3 hours after each levodopa dose, were compared. In de novo patients, we did not observe diurnal changes in motor score, whereas a progressive daytime worsening was visible in stable and wearing-off patients. No significant difference in levodopa pharmacokinetics after each levodopa dose was observed within each patient group, whereas 3OMD plasma levels significant increased with repeated levodopa administrations. However, no significant correlation between motor scores and 3OMD plasma levels was observed, suggesting that the diminishing motor response to afternoon and evening doses of levodopa in patients in long-term levodopa therapy does not relate to the pharmacokinetics of the drug. It is possible that this phenomenon may be an expression of the occurrence of tolerance to repeated doses of levodopa.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10682228     DOI: 10.1097/00002826-200001000-00006

Source DB:  PubMed          Journal:  Clin Neuropharmacol        ISSN: 0362-5664            Impact factor:   1.592


  18 in total

Review 1.  'The clocks that time us'--circadian rhythms in neurodegenerative disorders.

Authors:  Aleksandar Videnovic; Alpar S Lazar; Roger A Barker; Sebastiaan Overeem
Journal:  Nat Rev Neurol       Date:  2014-11-11       Impact factor: 42.937

Review 2.  Circadian and sleep disorders in Parkinson's disease.

Authors:  Aleksandar Videnovic; Diego Golombek
Journal:  Exp Neurol       Date:  2012-08-23       Impact factor: 5.330

3.  Circadian melatonin rhythm and excessive daytime sleepiness in Parkinson disease.

Authors:  Aleksandar Videnovic; Charleston Noble; Kathryn J Reid; Jie Peng; Fred W Turek; Angelica Marconi; Alfred W Rademaker; Tanya Simuni; Cindy Zadikoff; Phyllis C Zee
Journal:  JAMA Neurol       Date:  2014-04       Impact factor: 18.302

Review 4.  Thermodynamics in Neurodegenerative Diseases: Interplay Between Canonical WNT/Beta-Catenin Pathway-PPAR Gamma, Energy Metabolism and Circadian Rhythms.

Authors:  Alexandre Vallée; Yves Lecarpentier; Rémy Guillevin; Jean-Noël Vallée
Journal:  Neuromolecular Med       Date:  2018-03-23       Impact factor: 3.843

Review 5.  Overview of Sleep and Circadian Rhythm Disorders in Parkinson Disease.

Authors:  Priti Gros; Aleksandar Videnovic
Journal:  Clin Geriatr Med       Date:  2019-09-06       Impact factor: 3.076

Review 6.  A New Perspective for Parkinson's Disease: Circadian Rhythm.

Authors:  Siyue Li; Yali Wang; Fen Wang; Li-Fang Hu; Chun-Feng Liu
Journal:  Neurosci Bull       Date:  2016-12-19       Impact factor: 5.203

Review 7.  Sleep as a Therapeutic Target in the Aging Brain.

Authors:  Thierno M Bah; James Goodman; Jeffrey J Iliff
Journal:  Neurotherapeutics       Date:  2019-07       Impact factor: 7.620

Review 8.  Consequences of Circadian Disruption on Neurologic Health.

Authors:  Aleksandar Videnovic; Phyllis C Zee
Journal:  Sleep Med Clin       Date:  2015-09-26

Review 9.  Circadian system - A novel diagnostic and therapeutic target in Parkinson's disease?

Authors:  Aleksandar Videnovic; Gregory L Willis
Journal:  Mov Disord       Date:  2016-01-30       Impact factor: 10.338

10.  COMT inhibition with tolcapone in the treatment algorithm of patients with Parkinson's disease (PD): relevance for motor and non-motor features.

Authors:  Angelo Antonini; Giovanni Abbruzzese; Paolo Barone; Ubaldo Bonuccelli; Leonardo Lopiano; Marco Onofrj; Mario Zappia; Aldo Quattrone
Journal:  Neuropsychiatr Dis Treat       Date:  2008-02       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.